FIELD: medicine.
SUBSTANCE: what is presented is a polynucleotide coding a fused protein of telomerase reverse transcriptase (TERT) wherein an inactive version of TERT polypeptide is combined with a considerable portion of a subunit B of a heat-labile enterotoxin (LTB). It is shown that the fused protein under the invention induces an immune response in a mammal which in the preferential versions of the implementation is stronger than that induced by isolated wild-type TERT.
EFFECT: invention discloses preparing the fused protein with the version of hTERT and necessary genetic structures, particularly adenovirus vectors and plasmids, as well as host cells providing expression of a polynucleotide coding the fused protein under the invention.
7 cl, 19 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED PROTEINS OF CARCINOEMBRYONAL ANTIGEN | 2005 |
|
RU2380375C2 |
| NUCLEIC ACID SYNTHETIC MOLECULE (VERSIONS), MAMMAL CELL EXPRESSION VECTOR, MAMMAL HOST CELL AND METHOD OF EXPRESSING ANTIGEN PROTEIN OF HUMAN EPIDERMAL GROWTH FACTOR-2 (HER2/neu) OR SHORTENED FORM THEREOF | 2004 |
|
RU2397249C2 |
| GENETIC VECTOR Ad6/3-hTERT-GMCSF CONTAINING GENOMIC SEQUENCES OF RECOMBINANT ADENOVIRUS SEROTYPE 6, HUMAN TELOMERASE PROMOTER, HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GENE, AS WELL AS FIBER PROTEIN GENE WITH INSERTION OF FIBER KNOB DOMAIN OF ADENOVIRUS SEROTYPE 3 WITH INCREASED TRANSDUCTION INTO TUMOR CELLS | 2023 |
|
RU2814581C1 |
| F-PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS AND ITS USE | 2007 |
|
RU2464316C2 |
| MODIFIED SUPERCOILED PROTEINS WITH IMPROVED PROPERTIES | 2013 |
|
RU2677799C2 |
| MICROVESICLE AND METHOD FOR ITS PREPARATION | 2014 |
|
RU2693088C2 |
| DESIGNING OF CARCINOLYTIC ADENOVIRUS RECOMBINANT, SPECIFICALLY EXPRESSING IMMUNOMODULATORY FACTOR GM-CSF IN TUMORAL CELLS AND ITS APPLICATION | 2004 |
|
RU2361611C2 |
| INFLUENZA VIRUS NUCLEOPROTEIN BASED VACCINES | 2014 |
|
RU2662667C2 |
| ANTI-HCV VACCINE | 2003 |
|
RU2323744C2 |
| MULTIPURPOSE CANCER-SPECIFIC PROMOTERS AND USING THEM IN ANTI-CANCER THERAPY | 2013 |
|
RU2539764C2 |
